Passage BIO (PASG) Accumulated Expenses (2019 - 2026)
Passage BIO (PASG) posted quarterly Accumulated Expenses of $3.9 million for Q1 2026, up 148.41% year-over-year from $1.6 million in Q1 2025, and down 16.29% quarter-over-quarter from $4.7 million in Q4 2025.
Passage BIO (PASG) Accumulated Expenses (2019 - 2026) Analysis & Trends
Passage BIO's Accumulated Expenses history runs 8 years deep, the most recent figure standing at $3.9 million for Q1 2026.
- In Q1 2026, Accumulated Expenses rose 148.41% year-over-year to $3.9 million; the TTM figure through Mar 2026 stood at $3.9 million (up 148.41% YoY), while the FY2025 annual figure was $4.7 million, down 30.62% from the prior year.
- Accumulated Expenses for Q1 2026 stood at $3.9 million, down from $4.7 million in the prior quarter.
- The five-year high for Accumulated Expenses was $15.7 million in Q2 2022, with the low at $1.0 million in Q3 2024.
- The 5-year median for Accumulated Expenses is $7.0 million (2022), against an average of $7.8 million.
- The sharpest annual moves came in 2024 and 2025: Accumulated Expenses sank 92.71% in 2024, then surged 300.1% in 2025.
- Passage BIO's Accumulated Expenses stood at $8.4 million in 2022, then jumped by 38.17% to $11.7 million in 2023, then slumped by 42.53% to $6.7 million in 2024, then slumped by 30.62% to $4.7 million in 2025, then dropped by 16.29% to $3.9 million in 2026.
- Business Quant data shows PASG's Accumulated Expenses at $3.9 million in Q1 2026, $4.7 million in Q4 2025, and $4.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Passage BIO | 13.99 Mn | 13.99 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.57 Mn |
| Mar 31, 2026 | 3.90 Mn |
| Dec 31, 2025 | 4.65 Mn |
| Sep 30, 2025 | 4.00 Mn |
| Jun 30, 2025 | 4.07 Mn |
| Mar 31, 2025 | 1.57 Mn |
| Dec 31, 2024 | 6.71 Mn |
| Sep 30, 2024 | 1.00 Mn |
| Jun 30, 2024 | 3.61 Mn |
| Mar 31, 2024 | 7.48 Mn |
| Dec 31, 2023 | 11.67 Mn |
| Sep 30, 2023 | 13.71 Mn |
| Jun 30, 2023 | 13.16 Mn |
| Mar 31, 2023 | 10.91 Mn |
| Dec 31, 2022 | 8.45 Mn |
| Sep 30, 2022 | 7.01 Mn |
| Jun 30, 2022 | 15.69 Mn |
| Mar 31, 2022 | 15.23 Mn |
| Dec 31, 2021 | 20.05 Mn |
| Sep 30, 2021 | 13.27 Mn |